Citation Impact
Citing Papers
Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors
2010 Standout
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α
2007 Standout
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
2007 Standout
Suppression of Aging in Mice by the Hormone Klotho
2005 StandoutScience
Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth Factor 23
2012 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies
2008
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress
2004 Standout
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
2005 StandoutScience
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Sirtuins as regulators of metabolism and healthspan
2012 Standout
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
2009 StandoutNature
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
2004
A Role for AMP-Activated Protein Kinase in Contraction- and Hypoxia-Regulated Glucose Transport in Skeletal Muscle
2001
Evaluating the glucose tolerance test in mice
2008
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
2007
Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals
2006
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
2011 Standout
Transcriptional regulation by calcium, calcineurin, and NFAT
2003 Standout
Metformin increases the PGC-1α protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo
2006
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles
2003
Metabolic Implications of Dietary Trans‐fatty Acids
2009
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase
2002 Standout
Mitochondria: In Sickness and in Health
2012 Standout
The role of gut hormones in glucose homeostasis
2007
AMPK, insulin resistance, and the metabolic syndrome
2013
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
2014 StandoutNature
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
2004 Standout
Biology of Incretins: GLP-1 and GIP
2007 Standout
Cellular energy sensing and signaling by AMP-activated protein kinase
2007
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
2012
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
2006 Standout
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
2015
Type 2 diabetes
2017 Standout
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
2015 Standout
Intracellular Calcium and Myosin Isoform Transitions
2002
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
2014
Inactivation of PKCθ leads to increased susceptibility to obesity and dietary insulin resistance in mice
2006
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
The Physiology of Glucagon-like Peptide 1
2007 Standout
Molecular mechanisms of necroptosis: an ordered cellular explosion
2010 Standout
Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus
2006
What We Talk About When We Talk About Fat
2014 Standout
Mechanisms for Insulin Resistance: Common Threads and Missing Links
2012 Standout
Dose–response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats
2005
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Knockout of the α2 but Not α1 5′-AMP-activated Protein Kinase Isoform Abolishes 5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranosidebut Not Contraction-induced Glucose Uptake in Skeletal Muscle
2004
Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy
2009
Drug Treatment for Obesity in the Post-Sibutramine Era
2011
AMPK: a nutrient and energy sensor that maintains energy homeostasis
2012 Standout
The role of gut hormones in the regulation of body weight and energy homeostasis
2009
Prediabetes: a high-risk state for diabetes development
2012 Standout
Adipose Tissue as an Endocrine Organ
2004 Standout
Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP
2010 StandoutNobel
Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: A Review of Emerging Therapies for Type 2 Diabetes
2006
The Incretin Mimetic Exenatide as a Monotherapy in Patients with Type 2 Diabetes
2007
Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice
2010
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
Fluorine in medicinal chemistry
2007 Standout
Gut Microbiota in Health and Disease
2010 Standout
Insulin Sensitivity of Muscle Capillary Recruitment In Vivo
2004
Considerations in the Design of Hyperinsulinemic-Euglycemic Clamps in the Conscious Mouse
2006
Short-Term Overexpression of a Constitutively Active Form of AMP-Activated Protein Kinase in the Liver Leads to Mild Hypoglycemia and Fatty Liver
2005
Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction
2006 Standout
Invited Review: Effects of acute exercise and exercise training on insulin resistance
2002
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
1997 Standout
Tirzepatide Once Weekly for the Treatment of Obesity
2022 Standout
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
2009 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes
2004
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse
2009
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Effects of the Long-Acting Human Glucagon-Like Peptide-1 Analog Liraglutide on β-Cell Function in Normal Living Conditions
2007
Fiber Types in Mammalian Skeletal Muscles
2011 Standout
Thyroid Hormone Regulation of Metabolism
2014 Standout
Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1
2004
Physical Activity and Public Health in Older Adults
2007 Standout
Physical Activity/Exercise and Type 2 Diabetes
2004
Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis
2008
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Parent-of-origin effects on voluntary exercise levels and body composition in mice
2009
Long-term Drug Treatment for Obesity
2013
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Works of Amy E. Halseth being referenced
An Overview of Muscle Glucose Uptake during Exercise
1998
Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study
2007
Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations
2002
Mathematical Modeling Shows Exenatide Improved β-Cell Function in Patients with Type 2 Diabetes Treated with Metformin or Metformin and a Sulfonylurea
2006
Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial
2010
Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
2005
Early alterations in soleus GLUT-4, glucose transport, and glycogen in voluntary running rats
1994
Limitations to exercise- and maximal insulin-stimulated muscle glucose uptake
1998
Glucagon response to exercise is critical for accelerated hepatic glutamine metabolism and nitrogen disposal
2000
Analysis of insulin-stimulated skeletal muscle glucose uptake in conscious rat using isotopic glucose analogs
1998
Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study
2007
Role of Ca2+fluctuations in L6 myotubes in the regulation of the hexokinase II gene
2000
Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
2008
Overexpression of hexokinase II increases insulinand exercise-stimulated muscle glucose uptake in vivo
1999